A 2-dose version of the J&J vaccine formulated for Covid-19 provides 94% protection for the infection, as per the company —a 2-dose vaccine regimen of J&J’s Jannsen vaccine can be easily compared with the 2-dose regimen of Pfizer or Moderna.
Moreover, the company also highlighted that adding a booster in a vaccine of a single shot has raised the chances of immunity and might help the people in protection against infectious disease.
Johnson & Johnson: Covid vaccine booster increases protection to 94%
The company also released information about three of the studies while considering various dimensions of the Janssen vaccine, and said that the vaccine mainly provides people with long-lasting protection which could be boosted further with having an extra shot.
Dr. Mathai Mammen, who is a global head of Janssen R&D released a statement in which he said, “Our large real-world-evidence and Phase 3 studies confirm that the single-shot Johnson & Johnson vaccine provides strong and long-lasting protection against COVID-19-related hospitalizations”. He further added that “Our single-shot vaccine generates strong immune responses and long-lasting immune memory. And, when a booster of the Johnson & Johnson COVID-19 vaccine is given, the strength of protection against COVID-19 further increases.”
On February 27, the US Food and Drug Administration provided an emergency authorization to J&J’s single-dose vaccine. The shots were given to around 14.8 million people residing in America, as per the statistics revealed by the US Centers for Disease Control and Prevention.
The ongoing Phase 2 Trial of the company’s 2-dose regimen showed giving two doses based on a span of 56 days can provide 100% protection against Covid-19 and 94% protection against moderate Covid-19 in the US. In addition, on the global level, the 2-dose regimen provided around 75% of protection against moderate-to-severe Covid-19, the company officials said.
A second study revealed that people are given a booster shot within six months or longer after their first dose had a 12-fold increment in their antibodies- in comparison to a four-fold increase for people who got a 2-dose in two months. In short, the protection should be stronger if people get a booster later- according to Dr. Dan Barouch, head of Beth Israel Deaconess Center for Virology and Vaccine Research.
“If you wait longer and have a boost at six months or later then you likely will have a better boost,” said Barouch.
“Third, the company said a real-world evidence study of 390,000 people in the US, using health insurance records through July — so covering the Delta variant — showed the one-shot J&J vaccine was 81% effective at preventing hospitalizations.”
“Among 390,517 vaccinated and 1,524,153 matched unvaccinated individuals, vaccine effectiveness 79% for COVID-19 and 81% for COVID-19-related hospitalizations,” – as per the Janssen-led research team wrote in an online preprint.
Lastly, Barouch said that the J&J vaccine may appear to be less effective in some of the countries outside the United States because it was tested in different countries where variants were circulating that can evade protection offered by the vaccines.
Barouch said the J&J vaccine may appear less effective in countries outside the United States because it was tested in many countries when variants were circulating that can evade the protection offered by vaccines.